 |
|
|
| |
The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Erik Mogalian,1 Anita Mathias,1 Jenny Yang,1 Lisa Moorehead,1 Maria Hernandez,1 Kenneth Lasseter,2 Daniel K. Ries,3 Richard A. Robson,4 Gemot K. Klein5
1Gilead Sciences, Inc., Foster City, CA; 2Clinical Pharmacology of Miami, Inc., Miami, FL; 3Prism Clinical Research, St Paul, MN; 4Christchurch Clinical Studies Trust, Ltd, Christchurch, New Zealand; 5APEX GmbH, Bremen, Germany
|
| |
|
|
|
|
|
